These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 85488)

  • 1. Immunological analysis of A strain mice bearing the A-10 mammary adenocarcinoma.
    Tax A; Manson LA
    Cancer Res; 1979 May; 39(5):1739-47. PubMed ID: 85488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters.
    Paul RD; Ghaffar A; Sigel MM; Charyulu V; Lopez DM
    Anticancer Res; 1981; 1(2):63-9. PubMed ID: 6214206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the effector cells mediating an "innocent bystander" cytotoxicity reaction induced by a syngeneic mammary adenocarcinoma in mice.
    Paul RD; Padmanabhan R; Lopez DM
    Cancer Res; 1984 Oct; 44(10):4480-6. PubMed ID: 6467207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.
    Lopez PF; Parks WP; Lopez DM
    J Natl Cancer Inst; 1984 Mar; 72(3):725-32. PubMed ID: 6199544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immunoprophylaxis in mice using glutaraldehyde-treated syngeneic tumor cells.
    Frost P; Sanderson CJ
    Cancer Res; 1975 Oct; 35(10):2646-50. PubMed ID: 50879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface antigens in a rat colon cancer model: correlation with inhibition of tumor growth.
    Steele G; Sjogren HO
    Surgery; 1977 Jul; 82(1):164-9. PubMed ID: 877853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
    Hager JC; Miller FR; Heppner GH
    Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

  • 13. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a membrane carrier molecule common to embryonal and tumour-specific antigenic determinants expressed by a mouse transplantable tumour.
    Comoglio PM; Bertini M; Forni G
    Immunology; 1975 Aug; 29(2):353-64. PubMed ID: 51002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of platinum(II) complexes with histamine and radioiodinated histamine in a transplantable murine adenocarcinoma model.
    Garnuszek P; Karczmarczyk U; Maurin M
    Nucl Med Biol; 2008 Jul; 35(5):605-13. PubMed ID: 18589305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbodiimide enhancement of complement-dependent antibody-mediated tumor cell lysis in vitro and antitumor activity in vivo.
    Fawwaz RA; Tenforde TS; Mehlberg WH
    Cancer Res; 1975 Mar; 35(3):679-86. PubMed ID: 1116128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
    Fortner GW; Kuperman O; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1269-76. PubMed ID: 1080776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum therapy for radiation-induced impairment of immune resistance to metastasis.
    Vaage J; Agarwal S
    Cancer Res; 1977 Oct; 37(10):3556-60. PubMed ID: 908007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance.
    Leveson SH; Howell JH; Paolini NS; Tan MH; Holyoke ED; Goldrosen MH
    Cancer Res; 1979 Feb; 39(2 Pt 2):582-6. PubMed ID: 367584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.